Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301.

[1]  N. Curtin,et al.  Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells , 2009, British Journal of Cancer.

[2]  M. Barbacid,et al.  Cdk2 suppresses cellular senescence induced by the c-myc oncogene , 2010, Nature Cell Biology.

[3]  M. Henriksson,et al.  Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation , 2009, Proceedings of the National Academy of Sciences.

[4]  Thomas S. Lin,et al.  Flavopiridol in chronic lymphocytic leukemia: a concise review. , 2009, Clinical lymphoma & myeloma.

[5]  D. Geerts,et al.  Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells , 2009, Proceedings of the National Academy of Sciences.

[6]  A. Giordano,et al.  Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.

[7]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[8]  Shunichi Takeda,et al.  Cyclin-dependent kinases and cell-cycle transitions: does one fit all? , 2008, Nature Reviews Molecular Cell Biology.

[9]  L. Krasinska,et al.  Selective chemical inhibition as a tool to study Cdk1 and Cdk2 functions in the cell cycle , 2008, Cell cycle.

[10]  M. Méchali,et al.  Cdk1 and Cdk2 activity levels determine the efficiency of replication origin firing in Xenopus , 2008, The EMBO journal.

[11]  James R Bischoff,et al.  CDK inhibitors in cancer therapy: what is next? , 2008, Trends in pharmacological sciences.

[12]  T. Chiles,et al.  Inhibition of Cyclin-dependent Kinase-2 Induces Apoptosis in Human Diffuse Large B-cell Lymphomas , 2007, Cell cycle.

[13]  Andres J Klein-Szanto,et al.  Cdk2 deficiency decreases ras/CDK4-dependent malignant progression, but not myc-induced tumorigenesis. , 2007, Cancer research.

[14]  A. Tward,et al.  Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC , 2007, Nature Medicine.

[15]  A. Giordano,et al.  A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo , 2007, Oncogene.

[16]  J. Iqbal,et al.  N‐Acylated Sulfonamide Sodium Salt: A Prodrug of Choice for the Bifunctional 2‐Hydroxymethyl‐4‐(5‐phenyl‐3‐trifluoromethyl‐pyrazol‐1‐yl) Benzenesulfonamide Class of COX‐2 Inhibitors. , 2006 .

[17]  D. Tindall,et al.  CDK2-Dependent Phosphorylation of FOXO1 as an Apoptotic Response to DNA Damage , 2006, Science.

[18]  Kum Kum Khanna,et al.  Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. , 2006, Cancer research.

[19]  S. Emanuel,et al.  Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. , 2006, Bioorganic & medicinal chemistry letters.

[20]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Węsierska‐Gądek,et al.  Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein , 2006, Expert opinion on investigational drugs.

[22]  T. Golub,et al.  Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. , 2004, Cancer cell.

[23]  P. Kaldis,et al.  Cdk2 Knockout Mice Are Viable , 2003, Current Biology.

[24]  Pierre Dubus,et al.  Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice , 2003, Nature Genetics.

[25]  Frank McCormick,et al.  Proliferation of cancer cells despite CDK2 inhibition. , 2003, Cancer cell.

[26]  Jane A. Endicott,et al.  Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor , 2002, Nature Structural Biology.

[27]  S. van den Heuvel,et al.  S and G2 Phase Roles for Cdk2 Revealed by Inducible Expression of a Dominant-Negative Mutant in Human Cells , 2001, Molecular and Cellular Biology.

[28]  S. van den Heuvel,et al.  Distinct roles for cyclin-dependent kinases in cell cycle control. , 1993, Science.